Skip to Content
Merck
CN
All Photos(4)

Documents

MAC133

Sigma-Aldrich

Anti-Cas9 Antibody, clone 7A9

clone 7A9, from mouse

Sign Into View Organizational & Contract Pricing

Synonym(s):
dCas9
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

7A9, monoclonal

species reactivity (predicted by homology)

all

technique(s)

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1κ

shipped in

wet ice

target post-translational modification

unmodified

General description

Cas9 is an essential endonuclease in Streptococcus pyogenes serotype M1 that is part of that organism’s innate immunity system, or CRISPR (clustered regularly interspaced short palindromic repeat) adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and Cas9. Subsequently Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, and then trimmed by 3′-5′ exonucleolytically. DNA-binding requires protein and both RNA species. Cas9 probably recognizes a short motif in the CRISPR repeat sequences (the PAM or to help distinguish self versus nonself. Researchers hope to exploit the programmability and precise nature of Cas9 cleavage for more effective recombinant DNA technologies.

Specificity

MAC133 recognises both Cas9 and dCas9 (nuclease deficient Cas9)

Immunogen

N-Terminal domain of Cas9.

Application

Anti-Cas9 Antibody, clone 7A9 | MAC133 is an antibody against Cas9 Antibody for use in Western Blotting, Immunoprecipitation and Immunocytochemistry.
Research Category
Secondary & Control Antibodies
Research Sub Category
Secondary Antibodies Adsorbed for Dual Labeling
Western Blotting Analysis: 0.5 µg/mL from a representative lot detected Cas9 in 1 µg of Myc-Cas9 expressing HEK293 cell lysate.
Immunoprecipitation Analysis: A representative lot immunoprecipitated Cas9 in Flag-Cas9 and Myc-Cas9 expressing cell lysate (performed by an independent laboratory).

Quality

Evaluated by Western Blotting in HEK293 expressing Flag-Cas9 cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected Cas9 in 1 µg of HEK293 cell lysate expressing Flag-Cas9.

Target description

~160 kDa observed

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Guo-Xiang Ruan et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 25(2), 331-341 (2017-01-23)
As the most common subtype of Leber congenital amaurosis (LCA), LCA10 is a severe retinal dystrophy caused by mutations in the CEP290 gene. The most frequent mutation found in patients with LCA10 is a deep intronic mutation in CEP290 that
Brice Lagrange et al.
Nature communications, 9(1), 242-242 (2018-01-18)
Caspase-4/5 in humans and caspase-11 in mice bind hexa-acylated lipid A, the lipid moeity of lipopolysaccharide (LPS), to induce the activation of non-canonical inflammasome. Pathogens such as Francisella novicida express an under-acylated lipid A and escape caspase-11 recognition in mice.
Thomas Del'Guidice et al.
PloS one, 13(4), e0195558-e0195558 (2018-04-05)
Delivery of recombinant proteins to therapeutic cells is limited by a lack of efficient methods. This hinders the use of transcription factors or Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) ribonucleoproteins to develop cell therapies. Here, we report a soluble
Elif Eren et al.
EMBO reports, 21(11), e50829-e50829 (2020-10-31)
Inflammatory caspase-11 (rodent) and caspases-4/5 (humans) detect the Gram-negative bacterial component LPS within the host cell cytosol, promoting activation of the non-canonical inflammasome. Although non-canonical inflammasome-induced pyroptosis and IL-1-related cytokine release are crucial to mount an efficient immune response against
Garmen Yuen et al.
Nucleic acids research, 45(20), 12039-12053 (2017-10-17)
CRISPR/Cas9 is a powerful gene editing tool for gene knockout studies and functional genomic screens. Successful implementation of CRISPR often requires Cas9 to elicit efficient target knockout in a population of cells. In this study, we investigated the role of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service